Recombinant I2S Purification Using Four-Column Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapy for Hunter syndrome involves a cumbersome purification process using six chromatography columns, which is inefficient and costly, and the recombinant iduronate-2-sulfatase (I2S) protein often lacks sufficient Ca-formylglycine for optimal activity.
Innovation Solution
A simplified purification process using four chromatography steps, including anion-exchange, cation-exchange, mixed-mode, and hydrophobic interaction chromatography, achieves high purity and retention of Ca-formylglycine in recombinant I2S protein, suitable for enzyme replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If a six-column chromatography process is used for purifying recombinant I2S protein, then purification completeness is improved, but process complexity and cost increase
Solution Approach 1:
The patent combines multiple chromatography functions into a reduced four-column process. Specifically, it integrates capture and clarification functions in the first column, and combines purification steps in subsequent columns, thereby reducing the total number of columns from six to four while maintaining purification effectiveness
Solution Approach 2:
The patent segments the purification process into four distinct functional stages: (1) capture and clarification, (2) intermediate purification, (3) polishing, and (4) final purification. Each stage uses specific chromatography columns with defined properties to achieve cumulative purification效果
2Manufacturing precision
If a six-column chromatography process is used for purifying recombinant I2S protein, then purification completeness is improved, but production cost increases
Solution Approach 1:
The patent merges multiple purification functions into fewer steps, reducing the number of chromatography columns from six to four. This consolidation directly reduces equipment investment, operational costs, and manufacturing complexity while maintaining the required purification completeness for clinical use
Solution Approach 2:
The patent optimizes chromatography parameters including buffer compositions, flow rates, and column selection to achieve high purification efficiency in fewer steps. By carefully controlling these parameters, the process maintains purification quality while reducing the number of required columns and associated costs
3Manufacturing precision
If conventional purification process is used, then purification is achieved, but Ca-formylglycine retention is insufficient
Solution Approach 1:
The patent optimizes chromatography parameters including pH, ionic strength, and buffer compositions to create conditions that favor both purification and retention of Ca-formylglycine. The process controls these parameters at each stage to prevent enzyme degradation and maintain catalytic activity
Solution Approach 2:
The patent uses specifically selected chromatography media and buffer systems as intermediaries that protect the enzyme structure and Ca-formylglycine cofactor during purification. These intermediaries facilitate gentle separation that maintains enzyme integrity and activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved process results in recombinant I2S protein with high Ca-formylglycine content, meeting marketing purity requirements and enhancing bioavailability and lysosomal targeting, thus providing a cost-effective and efficient enzyme replacement therapy.
Implementation Method 1
anion-exchange chromatography
Implementation Method 2
cation-exchange chromatography
Implementation Method 3
mixed-mode chromatography
Implementation Method 4
hydrophobic interaction chromatography
Data Source
AI summary
The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.